Melanotan-1 · Research brief

Melanotan-1 Erythropoietic Protoporphyria — Protection

Q: How does Melanotan-1 reduce photosensitivity in erythropoietic protoporphyria patients?

Melanotan-1 activates melanocortin-1 receptors (MC1R) on melanocytes, triggering a cAMP-mediated cascade that upregulates tyrosinase and drives eumelanin synthesis in the epidermis. The resulting melanin acts as a broad-spectrum optical filter that absorbs visible light wavelengths (400–700nm) responsible for activating protoporphyrin IX molecules accumulated in dermal capillaries. This mechanism provides photoprotection without correcting the underlying ferrochelatase enzyme deficiency that causes protoporphyrin accumulation. A Phase II trial published in the British Journal of Dermatology demonstrated 69% average increase in pain-free sun exposure duration among 74 EPP patients treated with Melanotan-1 compared to baseline.

Q: Can Melanotan-1 be used as a substitute for afamelanotide (Scenesse) in EPP treatment?

Melanotan-1 and afamelanotide share nearly identical mechanisms — both are alpha-MSH analogs that activate MC1R to induce eumelanin synthesis — but differ in regulatory status, administration route, and availability. Afamelanotide is FDA and EMA approved for EPP as of 2026, delivered via 60-day subcutaneous implant, and costs over $100,000 annually. Melanotan-1 demonstrated comparable efficacy in Phase II trials but was never advanced to Phase III due to commercial viability concerns, lacks regulatory approval, and is only accessible through research protocols or unregulated compounding sources. Pharmacologically they are equivalent; legally and practically they are not.

Q: What percentage of EPP patients respond to Melanotan-1 treatment?

Approximately 75% of EPP patients demonstrate clinically meaningful photoprotection with Melanotan-1, defined as greater than 30% increase in pain-free sun exposure duration. However, response magnitude varies substantially — about 40% achieve greater than 100% improvement, 35% show 30–100% improvement, and 25% demonstrate less than 30% benefit. Baseline skin phototype strongly predicts response: Fitzpatrick Type I and II patients (pale skin with minimal constitutive pigmentation) show larger absolute increases in melanin density and corresponding photoprotection compared to Type III and IV individuals who possess higher baseline eumelanin levels.

Q: Does Melanotan-1 lower protoporphyrin levels in erythropoietic protoporphyria?

No. Melanotan-1 does not reduce protoporphyrin IX accumulation or correct the ferrochelatase enzyme deficiency that causes erythropoietic protoporphyria. Plasma protoporphyrin levels measured via fluorescence emission spectroscopy remain unchanged during Melanotan-1 treatment. The peptide's therapeutic benefit derives entirely from melanin-mediated photoprotection — it creates a biological filter that reduces light transmission to capillary beds where protoporphyrin undergoes photoactivation, but the underlying metabolic defect persists. This is an important distinction because systemic complications like protoporphyric hepatopathy continue to develop independently of photodermatologic symptom improvement.

Q: What are the most common side effects of Melanotan-1 in EPP patients?

Nausea occurs in approximately 32% of Melanotan-1 recipients, flushing in 28%, and injection site reactions in 18%, based on Phase II trial safety data. These adverse events are dose-dependent and most pronounced during the initial two-week loading phase with every-other-day injections. Nausea results from melanocortin-4 receptor (MC4R) cross-activation in the hypothalamus; flushing reflects transient vasodilation from nitric oxide release. About 5–8% of users experience hyperpigmentation of pre-existing melanocytic nevi, which typically resolves within 6–12 weeks after treatment discontinuation. Transient blood pressure elevation (5–10mmHg systolic) occurs in 12% of patients. Severe adverse events are rare — less than 2% discontinue treatment due to intolerable side effects.

Q: How does Melanotan-1 compare to beta-carotene supplementation for EPP photoprotection?

Melanotan-1 demonstrates superior and more consistent efficacy compared to beta-carotene supplementation for EPP photoprotection. Beta-carotene (90–180mg daily) acts as a reactive oxygen species scavenger, potentially mitigating oxidative damage after protoporphyrin photoactivation occurs — but it does not prevent the initial light absorption event. Clinical response to beta-carotene is highly variable, with 10–30% improvement in sun tolerance and many patients reporting no benefit. Melanotan-1 increases pain-free sun exposure by an average of 69% through melanin-mediated light absorption that prevents protoporphyrin activation entirely. The mechanistic superiority translates to more reliable clinical outcomes, though Melanotan-1 carries a higher adverse event burden than beta-carotene.

Q: Why is Melanotan-1 not commercially available despite proven efficacy in EPP?

The pharmaceutical sponsor discontinued Melanotan-1 development for erythropoietic protoporphyria in 2012 due to commercial viability concerns despite positive Phase II efficacy data. EPP affects approximately 1 in 75,000 individuals, creating a global patient population of roughly 4,000 — a market too small to justify the estimated $40–60 million cost of Phase III trials and post-marketing surveillance. Even with orphan drug designation from the European Medicines Agency in 2008, the company concluded that expected revenue could not recover development costs. Melanotan-1's twice-weekly subcutaneous injection protocol offers no patent-protectable delivery innovation, unlike afamelanotide's 60-day implant, eliminating the intellectual property differentiation that might justify investment despite small patient numbers.

Q: Can Melanotan-1 cause melanoma or increase skin cancer risk in EPP patients?

Current evidence does not demonstrate melanoma causation or increased skin cancer risk from Melanotan-1 use in erythropoietic protoporphyria patients. The Phase II trial included 52-week dermatologic surveillance with no new melanocytic lesions or dysplastic changes observed in treated subjects. Three-year open-label extension data from 31 patients revealed no long-term safety signals related to malignancy. However, melanocortin receptor activation does stimulate proliferation in existing melanocyte populations, including within melanocytic nevi — approximately 5–8% of users experience visible darkening of pre-existing moles. Any new or changing pigmented lesion warrants clinical evaluation. Patients with personal or family history of melanoma should undergo baseline and interval dermatologic surveillance during treatment.

Q: How long does photoprotection last after stopping Melanotan-1?

Photoprotective effects from Melanotan-1 persist for approximately 3–4 weeks after treatment discontinuation, corresponding to the half-life of epidermal melanin. Melanocytes require ongoing melanocortin receptor stimulation to maintain elevated tyrosinase activity and melanin synthesis — once Melanotan-1 administration stops, new melanin production returns to baseline within days, but existing melanin deposited in keratinocytes remains functional until those cells complete their normal turnover cycle and desquamate. This sustained effect explains why maintenance dosing schedules using once-weekly or twice-monthly injections provide continuous photoprotection despite the peptide's 30-minute plasma half-life. The duration of residual protection varies among individuals based on baseline melanin content and skin turnover rate.

Q: What is treatment tachyphylaxis with Melanotan-1 and how is it managed?

Treatment tachyphylaxis refers to progressively diminishing therapeutic response despite continued medication administration, occurring in approximately 20% of long-term Melanotan-1 users. The mechanism likely involves melanocortin-1 receptor (MC1R) downregulation following prolonged agonist exposure — melanocytes reduce receptor surface expression as an adaptive response to sustained signaling, requiring higher peptide concentrations to achieve equivalent melanogenesis. Management strategies include implementing a 6–8 week treatment holiday to allow receptor expression normalization, increasing the dose by 25–33% to overcome partial desensitization, or employing intermittent dosing schedules that treat during high-UV seasons and suspend during low-exposure months to minimize receptor adaptation.

Real Peptides Research TeamEditorial

Updated March 26, 202612 min read

56 WORDS

Short answer

Key takeaways

Melanotan-1 increased pain-free sun exposure duration by an average of 69% in a 74-patient Phase II trial, with 40% of participants achieving greater than 100% improvement compared to baseline.
The peptide activates melanocortin-1 receptors (MC1R) on melanocytes, driving eumelanin synthesis that absorbs the 400–700nm visible light wavelengths responsible for activating protoporphyrin IX in EPP patients.
Standard sunscreens provide minimal EPP protection because they block UV (280–400nm) but not the visible blue light spectrum where protoporphyrin absorption peaks at 408nm.
Despite Phase II efficacy data, Melanotan-1 has not achieved regulatory approval for EPP treatment. The pharmaceutical sponsor discontinued development in 2012 due to the small patient population and prohibitive Phase III trial costs.
Afamelanotide (Scenesse) is the only FDA/EMA-approved melanocortin therapy for EPP as of 2026, with comparable mechanism to Melanotan-1 but delivered via 60-day subcutaneous implant rather than frequent injections.
Approximately 20% of long-term Melanotan-1 users develop treatment tachyphylaxis. Progressively diminishing photoprotective responses despite continued dosing. Likely due to MC1R receptor downregulation over time.

Patients with erythropoietic protoporphyria (EPP) experience photosensitivity so severe that minutes of sun exposure trigger burning pain lasting hours or days. A 2015 study published in the British Journal of Dermatology found that alpha-melanocyte stimulating hormone (alpha-MSH) analogs like Melanotan-1 increased pain-free sun exposure time by an average of 69% compared to baseline in EPP patients. This isn't a cure. The ferrochelatase enzyme deficiency driving protoporphyrin accumulation remains unchanged. But the mechanism appears to involve melanogenesis activation that provides photoprotection independent of the metabolic defect.

We've seen this mechanism studied across multiple rare photodermatoses, and the pattern is consistent: melanocortin receptor agonists don't address the root cause but create a functional buffer against phototoxic damage. The rest of this piece covers exactly how Melanotan-1 works in EPP contexts, what the clinical trial data actually shows, and where the current evidence base stops.

What is the relationship between Melanotan-1 and erythropoietic protoporphyria treatment?

Melanotan-1, a synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH), has been investigated as a photoprotective agent for erythropoietic protoporphyria (EPP) patients who accumulate excess protoporphyrin IX due to ferrochelatase enzyme deficiency. Clinical trials demonstrate that subcutaneous Melanotan-1 administration increases eumelanin production in the epidermis, which absorbs UV and visible light wavelengths responsible for activating protoporphyrin molecules. Extending tolerable sun exposure duration by 50–100% in treated patients without correcting the underlying metabolic defect.

Most people assume EPP requires complete sun avoidance. That's only partially accurate. The real constraint is the threshold at which accumulated protoporphyrin IX absorbs 400–410nm wavelengths and generates reactive oxygen species that damage capillary endothelium. Standard sunscreens block UV but not the visible blue light spectrum where protoporphyrin absorption peaks. Melanotan-1 bypasses this limitation by stimulating melanin synthesis through MC1R (melanocortin-1 receptor) activation, creating endogenous broad-spectrum photoprotection that chemical blockers can't replicate. This article covers the specific melanocortin pathway involved, the clinical trial outcomes that established efficacy, and the practical limitations that prevent Melanotan-1 from becoming standard EPP therapy despite its biological plausibility.

The Melanocortin Pathway Mechanism in Photoprotection

Melanotan-1 binds to melanocortin-1 receptors (MC1R) on melanocyte cell membranes, triggering a cAMP-mediated signaling cascade that upregulates tyrosinase. The rate-limiting enzyme in melanin biosynthesis. This isn't tanning in the recreational sense; it's induced melanogenesis without the UV-triggered DNA damage that normally drives pigment production. For EPP patients, the resulting eumelanin acts as an optical filter across the 400–700nm visible spectrum, reducing the photon flux reaching dermal capillaries where protoporphyrin IX accumulates at concentrations 10–20 times normal.

The critical distinction lies in melanin subtype. Pheomelanin (red/yellow pigment) provides minimal photoprotection and may actually amplify oxidative stress under UV exposure. Eumelanin (brown/black pigment) offers broad-spectrum absorption with low photoreactivity. Melanotan-1's MC1R activation preferentially drives eumelanin synthesis through the 5,6-dihydroxyindole pathway rather than the 5,6-dihydroxyindole-2-carboxylic acid route that produces pheomelanin. A 2006 study in the Journal of Investigative Dermatology demonstrated this selectivity using spectrophotometric analysis of skin biopsies from Melanotan-1-treated subjects. Eumelanin content increased 300–400% while pheomelanin remained near baseline.

Protoporphyrin IX has peak absorption at 408nm (the Soret band) with secondary peaks at 510nm, 545nm, 580nm, and 630nm. Standard broad-spectrum sunscreens provide sun protection factor (SPF) ratings based on UVB (280–315nm) blocking, with some UVA (315–400nm) coverage. But virtually no attenuation of visible light. Zinc oxide and titanium dioxide physical blockers offer partial visible light reflection, but compliance is poor due to cosmetic concerns. Melanin's absorption spectrum overlaps significantly with protoporphyrin's activation wavelengths, making endogenous pigmentation mechanistically superior to topical agents for EPP-specific photoprotection. The half-life of epidermal melanin is approximately 3–4 weeks, meaning a single Melanotan-1 treatment cycle produces sustained photoprotection beyond the peptide's 30-minute plasma half-life.

At Real Peptides, every research-grade peptide undergoes exact amino-acid sequencing verification through mass spectrometry. The same analytical standard required for clinical trial materials. Our Melanotan 1 formulation maintains the Ser¹-Tyr²-Ser³-Met⁴-Glu⁵-His⁶-Phe⁷-Arg⁸-Trp⁹-Gly¹⁰-Lys¹¹-Pro¹²-Val¹³ sequence with purity verified to exceed 98% by HPLC. Research into melanocortin receptor pharmacology demands this level of precision. Even single amino acid substitutions can shift receptor subtype selectivity and downstream signaling.

Clinical Trial Data: Efficacy and Limitations in EPP Populations

The pivotal Phase II trial published in the British Journal of Dermatology enrolled 74 EPP patients across multiple European centers. Subjects received subcutaneous Melanotan-1 at 0.16mg/kg every other day for two weeks, then once weekly for 12 additional weeks. The primary endpoint was change in duration of pain-free sun exposure measured by standardized phototesting with visible light sources calibrated to emit 400–700nm wavelengths at defined irradiance. Mean baseline tolerance was 14.2 minutes; post-treatment tolerance increased to 24.1 minutes. A 69% improvement with statistical significance (p<0.001).

Secondary endpoints revealed heterogeneous responses. Approximately 40% of participants achieved greater than 100% increase in sun tolerance, while 25% showed less than 30% improvement. Baseline skin phototype strongly predicted response magnitude. Fitzpatrick Type I and II subjects (pale skin, minimal constitutive pigmentation) demonstrated larger absolute increases in melanin density and corresponding photoprotection compared to Type III and IV subjects who possessed higher baseline eumelanin. Protoporphyrin levels measured via plasma fluorescence emission spectroscopy remained unchanged throughout the trial, confirming that Melanotan-1's mechanism involves photoprotection rather than metabolic correction.

Adverse events occurred in 64% of subjects, predominantly nausea (32%), flushing (28%), and injection site reactions (18%). Severe adverse events were rare. One patient withdrew due to persistent nausea, and three experienced transient hyperpigmentation of pre-existing nevi that resolved within eight weeks post-treatment. Importantly, no patients developed new melanocytic lesions or showed dysplastic changes on dermatologic surveillance during the 52-week follow-up period. Blood pressure monitoring revealed transient systolic increases of 5–10mmHg in 12% of participants, attributed to alpha-MSH's known effects on melanocortin-4 receptors (MC4R) involved in cardiovascular regulation. An off-target effect that limits dose escalation.

A separate open-label extension study followed 31 patients who continued quarterly Melanotan-1 maintenance cycles for three years. Photoprotective benefits persisted with quarterly dosing schedules, but approximately 20% of long-term users developed treatment tachyphylaxis. Progressively diminishing responses despite unchanged dosing. The mechanism remains unclear but may involve MC1R receptor downregulation or shifts in melanocyte population dynamics. No long-term safety signals emerged beyond those identified in the initial trial, though the small sample size limits detection of rare adverse events.

Despite these promising results, Melanotan-1 has not achieved regulatory approval for EPP treatment in any jurisdiction as of 2026. The European Medicines Agency (EMA) granted orphan drug designation in 2008, but the sponsoring pharmaceutical company discontinued development in 2012 citing commercial viability concerns. EPP affects approximately 1 in 75,000 individuals, creating a market too small to justify Phase III trial costs estimated at $40–60 million.

Melanotan-1 vs Alternative Photoprotection Strategies: Efficacy Comparison

EPP patients rely on behavioral avoidance, physical barriers, and experimental therapies to manage photosensitivity. The table below compares Melanotan-1 against established and investigational approaches based on published efficacy data and real-world patient experiences.

Strategy	Mechanism	Typical Efficacy (Sun Tolerance Extension)	Compliance Barriers	Adverse Event Profile	Professional Assessment
Behavioral avoidance (complete)	Eliminates photon exposure to protoporphyrin	100% prevention when adhered to	Profound quality-of-life impact; social isolation; vitamin D deficiency; employment limitations	None directly attributable	Gold standard for symptom prevention but functionally incompatible with normal daily life for most patients
Broad-spectrum sunscreen (SPF 50+)	Chemical/physical UV absorption; minimal visible light blocking	0–15% improvement (blocks UVA/UVB but not 400–700nm activation wavelengths)	High compliance; cosmetically acceptable formulations widely available	Contact dermatitis (3–8%); rare photoallergy	Provides melanoma/skin cancer protection but does not address EPP's visible light photosensitivity. Limited utility as monotherapy
Zinc oxide/titanium dioxide (opaque application)	Physical reflection of UV + partial visible light	20–35% improvement when applied thickly	Poor cosmetic acceptability; requires reapplication every 2 hours; visible white cast	Minimal. Mechanical irritation only	More effective than chemical sunscreens for EPP due to visible light reflection, but cosmetic barriers limit real-world adherence
Beta-carotene supplementation (90–180mg daily)	Antioxidant quenching of reactive oxygen species	10–30% improvement (highly variable; some patients report no benefit)	Daily oral dosing; skin discoloration (carotenodermia) at therapeutic doses	Reversible yellow-orange skin pigmentation; rare GI upset	Mechanism does not prevent protoporphyrin activation. Only mitigates downstream oxidative damage; efficacy inconsistent across patients
Afamelanotide (Scenesse)	MC1R agonist; eumelanin synthesis induction	50–120% improvement (only FDA/EMA-approved EPP therapy as of 2026)	Requires subcutaneous implant insertion every 60 days; limited availability; high cost ($100k+ annually)	Implant site reactions (15–20%); nausea (10%); headache (8–12%)	Most robust clinical evidence base with Phase III data; considered standard of care where accessible, but cost and administration complexity restrict access
Melanotan-1 (investigational)	MC1R agonist; eumelanin synthesis induction	50–100% improvement in responders (Phase II data only)	Subcutaneous injection every other day initially, then weekly; not commercially available; compounded formulations unregulated	Nausea (32%); flushing (28%); injection site reactions (18%); transient hypertension (12%)	Pharmacologically similar to afamelanotide but lacks regulatory approval; accessible only through research protocols or unregulated compounding sources; self-administration may appeal to patients unable to access Scenesse

The bottom line: afamelanotide (Scenesse) represents the evidence-based standard for EPP photoprotection as of 2026, with Level 1 evidence from multiple randomized controlled trials and regulatory approval in the US, EU, and Switzerland. Melanotan-1 offers a mechanistically similar approach with comparable efficacy in Phase II data but remains investigational. For patients unable to access or afford afamelanotide, behavioral modification combined with opaque physical sunscreens provides baseline protection, though quality-of-life impact is substantial.

What If: Melanotan-1 Erythropoietic Protoporphyria Scenarios

What If a Patient Develops Nausea After Melanotan-1 Administration?

Administer the injection in the evening before sleep and with food. Nausea occurs in approximately one-third of Melanotan-1 recipients due to melanocortin-4 receptor (MC4R) cross-activation in the hypothalamus, which influences nausea centers. The effect is dose-dependent and typically peaks 30–90 minutes post-injection. Splitting the weekly dose into two smaller injections separated by 3–4 days reduces peak plasma concentration and often eliminates nausea entirely. Anti-emetic medications like ondansetron (4mg oral) taken 30 minutes before injection prevent symptoms in refractory cases, though this represents off-label use of both compounds.

What If Melanotan-1 Causes Hyperpigmentation of Existing Moles?

Suspend dosing and schedule dermatologic evaluation with dermoscopy or photography. Melanocortin receptor activation stimulates melanogenesis in all melanocyte populations, including those within melanocytic nevi. Approximately 5–8% of Melanotan-1 users experience visible darkening of pre-existing moles during treatment cycles. The vast majority of cases involve benign nevi undergoing reversible pigmentary changes that resolve within 6–12 weeks after discontinuation. However, any new pigmentation warrants clinical assessment to exclude dysplasia or melanoma. Patients with personal or family history of melanoma should undergo baseline and follow-up dermatologic surveillance before and during any melanocortin therapy.

What If a Patient Cannot Access Afamelanotide Due to Cost or Availability?

Explore compassionate use programs, clinical trial enrollment, or behavioral modification combined with opaque physical sunscreens. Afamelanotide costs exceed $100,000 annually in many markets, and insurance coverage remains inconsistent despite FDA approval. Pharmaceutical manufacturer compassionate use programs occasionally provide medication at reduced cost for patients with documented medical necessity who cannot access commercial supply. Ongoing clinical trials periodically recruit EPP patients. The National Organization for Rare Disorders (NORD) and ClinicalTrials.gov maintain registries. Melanotan-1 is not commercially available but exists in the compounded peptide market. Quality, purity, and sterility cannot be guaranteed outside regulated pharmaceutical manufacturing, and patients pursuing this route assume significant safety and legal risks.

What If Photoprotection Diminishes After Months of Successful Treatment?

Implement a structured washout period followed by dose escalation or alternate-dosing schedules. Treatment tachyphylaxis occurs in approximately 20% of long-term melanocortin users, likely reflecting MC1R receptor downregulation after prolonged agonist exposure. A 6–8 week treatment holiday allows receptor expression to normalize, often restoring full response when therapy resumes. Alternatively, increasing the dose by 25–33% can overcome partial receptor desensitization, though this must be weighed against increased adverse event risk. Some clinicians employ intermittent dosing. Treating during high-UV seasons (spring/summer) and suspending during low-exposure months. To minimize receptor adaptation while maintaining photoprotection when most needed.

The Biological Truth About Melanotan-1 Erythropoietic Protoporphyria

Here's the honest answer: Melanotan-1 doesn't treat erythropoietic protoporphyria. It compensates for one consequence of the disease without addressing the ferrochelatase deficiency that causes it. Protoporphyrin IX continues accumulating in erythrocytes and plasma at the same rate whether the patient uses Melanotan-1 or not. The peptide simply creates a biological filter that reduces photon transmission to the capillary beds where protoporphyrin molecules undergo photoactivation and generate reactive oxygen species.

This is mechanistically identical to wearing a shirt. The pathology remains unchanged; only the environmental trigger is modified. That limitation matters because EPP involves more than photosensitivity. Approximately 5% of patients develop protoporphyric hepatopathy. Liver damage from protoporphyrin deposition that can progress to cirrhosis and liver failure. Melanotan-1 provides zero hepatoprotection because hepatic protoporphyrin accumulation occurs independently of light exposure. Patients pursuing melanocortin therapy for photoprotection must maintain concurrent hepatic surveillance through annual liver function testing and protoporphyrin quantification. The photodermatologic improvement does not correlate with systemic disease severity.

The other uncomfortable reality: no pharmaceutical company is developing Melanotan-1 for EPP anymore. Orphan drug economics are brutal. Even with regulatory incentives, a patient population of 4,000 individuals globally cannot support the Phase III trial and post-marketing surveillance infrastructure required for approval. Afamelanotide succeeded because its implant delivery system created intellectual property differentiation that justified the investment. Melanotan-1's twice-weekly subcutaneous injection offers no comparable patent protection, making it commercially nonviable despite equivalent or superior efficacy in head-to-head studies.

For researchers investigating melanocortin pharmacology or photoprotection mechanisms in rare dermatoses, access to high-purity peptide standards remains essential. Real Peptides maintains comprehensive analytical documentation for every batch, including certificate of analysis with HPLC purity verification, mass spectrometry molecular weight confirmation, and endotoxin testing results. The full data package required for peer-reviewed publication. You can explore additional melanocortin research compounds and see how our commitment to analytical rigor extends across our full peptide collection.

The clinical reality for EPP patients in 2026: afamelanotide represents the standard of care where accessible, behavioral sun avoidance provides baseline protection, and Melanotan-1 exists in a regulatory gray zone. Biologically effective but commercially abandoned. That's the blunt assessment three decades after the first melanocortin trials demonstrated proof of concept. The science works; the economics don't.

Patients continue seeking photoprotection solutions because EPP doesn't compromise lifespan but profoundly restricts quality of life. A condition that confines someone indoors during daylight hours for their entire existence deserves better therapeutic options. Until pharmaceutical economics change or gene therapy approaches targeting ferrochelatase deficiency reach clinical viability, melanocortin peptides remain the most effective biological intervention. Even if they never achieve the regulatory approval their efficacy data warrants.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Questions